POIESIS: A randomized, double-blind, placebo-controlled, multicenter, global phase 3 study of navtemadlin as add-on to ruxolitinib in JAK inhibitor-naive patients with myelofibrosis who have a suboptimal response to ruxolitinib Meeting Abstract
| Authors: | Vachhani, P.; Rampal, R.; Bradley, T.; Harrison, C.; Jain, T.; Kuykendall, A. T.; Palandri, F.; Mascarenhas, J. O.; Al-Ali, H. K.; Passamonti, F.; Nekhymchuk, A.; Foss, H.; Rothbaum, W.; Verstovsek, S.; Heidel, F. |
| Abstract Title: | POIESIS: A randomized, double-blind, placebo-controlled, multicenter, global phase 3 study of navtemadlin as add-on to ruxolitinib in JAK inhibitor-naive patients with myelofibrosis who have a suboptimal response to ruxolitinib |
| Meeting Title: | 66th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 144 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Dec 7-10 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-11-05 |
| Start Page: | 18083 |
| End Page: | 18084 |
| Language: | English |
| ACCESSION: | WOS:001414558300050 |
| DOI: | 10.1182/blood-2024-200966 |
| PROVIDER: | wos |
| Notes: | Source: Wos |
